Global Patent Index - EP 3289083 A4

EP 3289083 A4 20181219 - NUCLEOSIDE-MODIFIED RNA FOR INDUCING AN ADAPTIVE IMMUNE RESPONSE

Title (en)

NUCLEOSIDE-MODIFIED RNA FOR INDUCING AN ADAPTIVE IMMUNE RESPONSE

Title (de)

NUKLEOSIDMODIFIZIERTE RNA ZUR INDUKTION EINER ADAPTIVEN IMMUNANTWORT

Title (fr)

ARN À NUCLÉOSIDE MODIFIÉ DESTINÉ À INDUIRE UNE RÉPONSE IMMUNITAIRE ADAPTATIVE

Publication

EP 3289083 A4 20181219 (EN)

Application

EP 16787068 A 20160427

Priority

  • US 201562153143 P 20150427
  • US 2016029572 W 20160427

Abstract (en)

[origin: WO2016176330A1] The present invention relates to compositions and methods for inducing adaptive immune response in a subject. In certain embodiments, the present invention provides a composition comprising a nucleoside-modified nucleic acid molecule encoding an antigen, adjuvant, or a combination thereof. For example, in certain embodiments, the composition comprises a vaccine comprising a nucleoside-modified nucleic acid molecule encoding an antigen, adjuvant, or a combination thereof.

IPC 8 full level

C12N 15/11 (2006.01); A61K 9/127 (2006.01); A61K 31/7115 (2006.01); A61K 31/712 (2006.01); C07C 219/08 (2006.01); C07D 295/13 (2006.01)

CPC (source: EP US)

A61K 9/0019 (2013.01 - US); A61K 9/127 (2013.01 - EP US); A61K 31/7115 (2013.01 - EP US); A61K 31/712 (2013.01 - EP US); A61K 39/0011 (2013.01 - EP US); A61K 39/002 (2013.01 - EP US); A61K 39/02 (2013.01 - EP US); A61K 39/12 (2013.01 - US); A61K 39/145 (2013.01 - US); A61P 31/16 (2018.01 - EP US); A61P 31/18 (2018.01 - EP US); C07C 219/08 (2013.01 - EP US); C07D 295/13 (2013.01 - EP US); C08G 65/33306 (2013.01 - EP); C08G 65/33337 (2013.01 - EP); C08G 65/33396 (2013.01 - EP); C12N 15/11 (2013.01 - US); A61K 2039/51 (2013.01 - EP US); A61K 2039/55555 (2013.01 - EP US); A61P 35/00 (2018.01 - EP US)

Citation (search report)

  • [XY] US 2011300205 A1 20111208 - GEALL ANDREW [US], et al
  • [XP] WO 2015164674 A1 20151029 - MODERNA THERAPEUTICS INC [US]
  • [XP] WO 2015199952 A1 20151230 - ACUITAS THERAPEUTICS INC [CA]
  • [E] WO 2017075531 A1 20170504 - ACUITAS THERAPEUTICS INC [CA]
  • [Y] D. N. NGUYEN ET AL: "Lipid-derived nanoparticles for immunostimulatory RNA adjuvant delivery", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 109, no. 14, 3 April 2012 (2012-04-03), pages E797 - E803, XP055285231, ISSN: 0027-8424, DOI: 10.1073/pnas.1121423109 & D. N. NGUYEN ET AL: "Lipid-derived nanoparticles for immunostimulatory RNA adjuvant delivery", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 109, no. 14, 15 March 2012 (2012-03-15), pages SE797/1 - SE803/11, XP055346302, ISSN: 0027-8424, DOI: 10.1073/pnas.1121423109
  • [Y] KATHRYN A WHITEHEAD ET AL: "Synergistic Silencing: Combinations of Lipid-like Materials for Efficacious siRNA Delivery", MOLECULAR THERAPY, vol. 19, no. 9, 1 September 2011 (2011-09-01), pages 1688 - 1694, XP055067340, ISSN: 1525-0016, DOI: 10.1038/mt.2011.141
  • [XP] NORBERT PARDI ET AL: "Expression kinetics of nucleoside-modified mRNA delivered in lipid nanoparticles to mice by various routes", JOURNAL OF CONTROLLED RELEASE, vol. 217, 1 November 2015 (2015-11-01), NL, pages 345 - 351, XP055231069, ISSN: 0168-3659, DOI: 10.1016/j.jconrel.2015.08.007
  • [A] LUIS A BRITO ET AL: "A Cationic Nanoemulsion for the Delivery of Next-generation RNA Vaccines", MOLECULAR THERAPY, vol. 22, no. 12, 16 July 2014 (2014-07-16), pages 2118 - 2129, XP055180488, ISSN: 1525-0016, DOI: 10.1038/mt.2014.133

Citation (examination)

  • MARTIN A MAIER ET AL: "Biodegradable Lipids Enabling Rapidly Eliminated Lipid Nanoparticles for Systemic Delivery of RNAi Therapeutics", MOLECULAR THERAPY, vol. 21, no. 8, 1 August 2013 (2013-08-01), pages 1570 - 1578, XP055551712, ISSN: 1525-0016, DOI: 10.1038/mt.2013.124
  • See also references of WO 2016176330A1

Designated contracting state (EPC)

AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DOCDB simple family (publication)

WO 2016176330 A1 20161103; AU 2016253972 A1 20171214; AU 2016253972 B2 20200102; AU 2020202322 A1 20200423; AU 2022263594 A1 20221222; CA 2984125 A1 20161103; EP 3289083 A1 20180307; EP 3289083 A4 20181219; JP 2018526321 A 20180913; JP 2021138741 A 20210916; JP 2024084804 A 20240625; JP 7506030 B2 20240625; US 2018303925 A1 20181025; US 2022040285 A1 20220210; US 2022226461 A1 20220721

DOCDB simple family (application)

US 2016029572 W 20160427; AU 2016253972 A 20160427; AU 2020202322 A 20200401; AU 2022263594 A 20221104; CA 2984125 A 20160427; EP 16787068 A 20160427; JP 2017556248 A 20160427; JP 2021096084 A 20210608; JP 2024060190 A 20240403; US 201615569546 A 20160427; US 202117371261 A 20210709; US 202217705837 A 20220328